Article

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion

2021-12-01

Abstract excerpt

<h4>ABSTRACT</h4> Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8 + T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal target to deliver antigens. cDC1s uniquely express XCR1, a seven transmembrane G protein-coupled receptor (GPCR). Due to its restricted expression and endocytic nature,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0ff23619-d9de-50cd-ade8-22f87e3f718f
DOI: 10.1101/2021.11.30.470538

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansionDOI 10.1101/2021.11.30.470538Read

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatmentSemantic proximity Read

Combination of NY-ESO-1-TCR-T-cells coengineered to secrete SiRPα decoys with anti-tumor antibodies to augment macrophage phagocytosisSemantic proximity Read

The Role of XCR1 and its Ligand XCL1 in Antigen Cross-Presentation by Murine and Human Dendritic CellsSemantic proximity Read

Rewiring dendritic cell function with CLEC9A and DEC205-based chimeric antigen receptorsSemantic proximity Read

Repurposed endogenous virus-like vesicles mediate dendritic cell long-range antigen presentation and T cell activation for enhanced cancer vaccinationSemantic proximity Read

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.Semantic proximity Read

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.Semantic proximity Read

Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141+XCR1+ dendritic cellsSemantic proximity Read

PD-1 blockade-driven anti-tumor CD8 <sup>+</sup> T cell immunity requires XCR1 <sup>+</sup> dendritic cellsSemantic proximity Read

Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificitySemantic proximity Read

Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansionSemantic proximity Read

Antigen Cross-Presentation of Immune ComplexesSemantic proximity Read